Ontario Leading Fight Against Breast Cancer

January 23, 2009 CPDC

McGuinty Government Supporting New Approach To Early Detection

HAMILTON: JANUARY 23, 2009 – Ontario has been chosen to lead the development and evaluation of new technologies for detecting breast cancer.

Hamilton was selected by GE Healthcare to be the first site in the world to receive new prototype technologies for use in a molecular breast imaging research program. Hamilton researchers will design and lead clinical trials to evaluate new technologies which use molecular imaging probes that target breast cancer. This cutting-edge strategy has the potential to find very small tumours, leading to early intervention. Trials will be geared towards high-risk women who are not currently well served by mammography.

GE Healthcare chose Hamilton because of the strong partnership among the Ontario Institute for Cancer Research, the Centre for Probe Development and Commercialization, and the Oncology and Nuclear Medicine programs at McMaster University and Hamilton Health Sciences.

The Ministry of Research and Innovation has committed almost $435 million since 2003 to support the world-leading work of these institutions, and is contributing $450,000 toward the project through the Ontario Institute for Cancer Research.


“The scientific breakthroughs we make here will help Ontario families – and millions of people around the world – to live better, healthier, longer lives,” said Minister of Research and Innovation John Wilkinson.

“Our goal is for cancer to be diagnosed at the earliest stage. These technologies may have a significant impact on care for high-risk patients whose tiny tumours cannot be seen by mammography. We hope this will lead to earlier detection, better treatment and ultimately, save lives,” said Dr. Tom Hudson, President and Scientific Director, Ontario Institute for Cancer Research.

“The opening of the Centre for Probe Development and Commercialization (CPDC) in Hamilton has resulted in a link between government, researchers, healthcare providers and industry. The CPDC and its partners are working to develop and evaluate cutting edge technologies, which may have the potential to detect and diagnose diseases like cancer earlier and with greater accuracy than is now possible,” said Dr. John Valliant, CEO and Scientific Director.


• Each year in Ontario, 8,500 women are diagnosed with breast cancer.

• According to the Mayo Clinic, when localized breast cancer is caught at an early stage, the survival rate is 98 per cent.

• Ontario is the largest hub of life sciences activity in Canada and the fourth largest biomedical research centre in North America.


Find out more about the Ontario Institute for Cancer Research.

Find out more about Ontario’s Innovation Agenda.

For more information, please contact:

T: 905-525-9140, ext 21212
E: info@imagingprobes.ca

More news from CPDC

CPDC joins forces with the Canadian Nuclear Isotope Council

Hamilton, Ontario, February 19, 2019 – As Canada strives to maintain a leadership position in science and technology, the Centre for Probe Development and Commercialization (CPDC), located at McMaster University, has partnered with the Canadian Nuclear Isotope Council (CNIC) to ensure Canada remains at the forefront of medical isotope R&D and production, and to advocate

Centre for Probe Development and Commercialization (CPDC) Appoints New Head of Business Development

Hamilton, Ontario, November 16, 2018 – The Centre for Probe Development and Commercialization (CPDC) is proud to introduce the new Head of Business Development, Bruno Paquin, PhD. Bruno comes to us with years of experience in research and development and he brings with him extensive knowledge of scientific operations in life and health sciences, as

Centre for Probe Development & Commercialization (CPDC) Appoints New CEO and President

Hamilton, Ontario, October 3, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, today is announcing that its founder, Dr. John Valliant, has stepped down from his role as CEO to focus his time as the CEO of Fusion Pharmaceuticals. Dr. Valliant will

For more information contact us at: